With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data and giving denosumab every 3 months as well?
Answer from: Medical Oncologist at Academic Institution
Not without data. The long half life and persistence of bisphosphonates in the bone is different from the shorter half life of monoclonal antibodies targeting RANK ligand (32 days). So dosing denosumab 120mg every 3 months would probably lead to suboptimal drug levels and increased bone turnover. Wh...
Comments
Medical Oncologist at Yuma Regional Medical Center Cancer Center RANKL inhibitors have a shorter half-life and as s...
RANKL inhibitors have a shorter half-life and as s...